The TGF-β1, TNF-α, IL-1β, IL-6, MMP9, and TGF-β1 which had higher degree value may be the key targets for the treatment of GN by active ingredients of PS, as shown in Figure 2(b). The gene discussed is MMP9; the disease is ganglioneuroma.